Kronos Bio, Inc. announced a streamlined leadership structure designed to focus on pipeline advancement and align with Kronos Bio?s current operating needs. As part of this effort, Kronos Bio has eliminated three executive officer roles including the Chief Medical Officer, Chief Scientific Officer, and Chief Operating Officer and General Counsel. As a result, Jorge DiMartino, M.D., Ph.D., Christopher Dinsmore, Ph.D., and Barbara Kosacz, J.D., will be departing the Company.

To ensure a smooth transition, they will remain with the Company through February 16, 2024. All three executives will remain strategic advisors to Kronos Bio. The Executive Leadership team, reporting to Dr. Bischofberger, now inludes: Charles Lin, Ph.D., Senior Vice President, Research and Development; Elizabeth Olek, DO, Senior Vice President, Clinical Development; Rocio Martin Hoyos, Senior Vice President, Corporate Strategy and Portfolio Management; Allison Frisbee, Senior Vice President, Corporate Operations and Legal.